AbbVie Enters Into Collaboration And Option-To-License Agreement With Gilgamesh Pharmaceuticals For Therapies For Psychiatric Disorders
Portfolio Pulse from Benzinga Newsdesk
AbbVie has entered into a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation neuroplastogens for psychiatric disorders. This partnership combines AbbVie's expertise in psychiatry with Gilgamesh's innovative research platform.
May 13, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's collaboration with Gilgamesh Pharmaceuticals to develop neuroplastogens for psychiatric disorders could enhance its portfolio in the psychiatry market.
The collaboration with Gilgamesh Pharmaceuticals allows AbbVie to potentially expand its psychiatry portfolio with innovative treatments. Given the focus on developing next-generation neuroplastogens, this partnership could lead to significant advancements in treatments for psychiatric disorders, positioning AbbVie favorably in the market.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80